Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation

BACKGROUND: Asthma is an allergic airway inflammation-driven disease that affects more than 300 million people worldwide. Targeted therapies for asthma are largely lacking. Although asthma symptoms can be prevented from worsening, asthma development can’t be prevented. Cdc42 GTPase has been shown to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Exp Allergy
Asıl Yazarlar: Yang, Jun-Qi, Kalim, Khalid W., Li, Yuan, Duan, Xin, Nguyen, Phuong, Khurana Hershey, Gurjit K., Kroner, John, Ruff, Brandy, Zhang, Li, Salomonis, Nathan, Rochman, Mark, Wen, Ting, Zheng, Yi, Guo, Fukun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6310654/
https://ncbi.nlm.nih.gov/pubmed/30307073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cea.13293
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller